“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD. Six-month ...

An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced ...

"A 14-month delay in disease progression is a very meaningful end point to our patients, because that basically means delay in symptoms, delay in fractures, [and] delay in pain in the ...

"I would also like us to be able to reliably use even smaller scopes, but keep them efficient," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, shares her thoughts on areas for ongoing ...

"I'm so excited about them finally removing this boxed warning," says Helen L. Bernie, DO, MPH. The FDA’s recent announcement of class-wide labeling changes for testosterone products was met with ...

"In terms of how I select patients, I really look at the timing of metastatic disease, so whether it's metachronous or synchronous and the volume, and I think at this stage, the data are most robust ...

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD. The final patient visit has been ...

"It is important for us to ask patients whether they want to intensify or not, and not make assumptions," says Alicia Morgans, MD, MPH. In this video, Alicia Morgans, MD, MPH, shares insights from the ...

“Interestingly, the patients that were more likely to follow-up were those patients that were seen and established within our urology clinic,” says Christina B. Ching, MD. In this interview, Christina ...

The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...

"The primary end point was radiographic progression-free survival, which we reported in 2023, and we updated the radiographic progression-free survival data in 2025," says Neeraj Agarwal, MD, FASCO.

“Now, at 1 year, the 1-hour pad test has been done again, as it's part of the protocol, and she suffered 4 g of incontinence on this test, opposed to 125 g at the beginning,” says Emmanuel ...